Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Ray Comenzo, MD, Discusses ANDROMEDA Trial in AL Amyloidosis Patients
The ANDROMEDA trial is a trial that is extremely important for patients who have systemic light chain or AL-amyloidosis. I’d like to begin by thanking Janssen Oncology, the investigators on the study, and, particularly, the brave patients who enrolled on the first part of the study, which is called a ramp-in.
The study itself is a phase 3 trial asking whether or not the addition of the monoclonal antibody daratumumab to a standard treatment combination called CyBorD will benefit patients who are newly diagnosed with systemic amyloidosis. Daratumumab is an approved agent for multiple myeloma.
myBinderRelated Content
-
Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) for...The Janssen Pharmaceutical Companies of ...
-
Emerging Therapeutic Targets Currently Under Investigation for the Treatment of Systemic AmyloidosisSystemic amyloidosis occurs when one of ...
-
Clinical Profile and Treatment Outcome of Older (>75 years) Patients With Systemic AL AmyloidosisSystemic AL amyloidosis, a disease with ...
-
Sorrento STI-6129 ADC Initial Human Study Updatehttps://www.youtube.com/watch?v=uF4TmRus...
-
Management of Systemic AL Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific...Systemic AL amyloidosis is a plasma cell...
-
Systemic AmyloidosisTissue deposition of protein fibrils cau...
-
Case Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two PatientsImmunoglobulin light-chain amyloidosis (...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
